JAKUBIKOVA, Michala, Michaela TYBLOVA, Adam TESAR, Magda HORÁKOVÁ, Daniela VLAŽNÁ, Rysankova RYSANKOVA, Iveta NOVAKOVA, Doleckova DOLECKOVA, Dusek DUSEK, Jiri PITHA, Stanislav VOHÁŇKA and Josef BEDNAŘÍK. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival (Letter). European Journal of Neurology. Oxford: Rapid Science Ltd., 2022, vol. 29, No 1, p. "E7"-"E8", 2 pp. ISSN 1351-5101. Available from: https://dx.doi.org/10.1111/ene.15158. |
Other formats:
BibTeX
LaTeX
RIS
@article{1812594, author = {Jakubikova, Michala and Tyblova, Michaela and Tesar, Adam and Horáková, Magda and Vlažná, Daniela and Rysankova, Rysankova and Novakova, Iveta and Doleckova, Doleckova and Dusek, Dusek and Pitha, Jiri and Voháňka, Stanislav and Bednařík, Josef}, article_location = {Oxford}, article_number = {1}, doi = {http://dx.doi.org/10.1111/ene.15158}, keywords = {corticosteroids; COVID-19; immunosuppression; myasthenia gravis; rituximab}, language = {eng}, issn = {1351-5101}, journal = {European Journal of Neurology}, title = {Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival (Letter)}, url = {https://onlinelibrary.wiley.com/doi/10.1111/ene.15158}, volume = {29}, year = {2022} }
TY - JOUR ID - 1812594 AU - Jakubikova, Michala - Tyblova, Michaela - Tesar, Adam - Horáková, Magda - Vlažná, Daniela - Rysankova, Rysankova - Novakova, Iveta - Doleckova, Doleckova - Dusek, Dusek - Pitha, Jiri - Voháňka, Stanislav - Bednařík, Josef PY - 2022 TI - Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival (Letter) JF - European Journal of Neurology VL - 29 IS - 1 SP - "E7"-"E8" EP - "E7"-"E8" PB - Rapid Science Ltd. SN - 13515101 KW - corticosteroids KW - COVID-19 KW - immunosuppression KW - myasthenia gravis KW - rituximab UR - https://onlinelibrary.wiley.com/doi/10.1111/ene.15158 N2 - Background and purpose Myasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of coronavirus 2019 (COVID-19) mainly due to respiratory muscle weakness, older age and long-term immunosuppressive treatment. We aimed to define factors predicting the severity of COVID-19 in MG patients and risk of MG exacerbation during COVID-19. Methods We evaluated clinical features and outcomes after COVID-19 in 93 MG patients. Results Thirty-five patients (38%) had severe pneumonia and we recorded 10 deaths (11%) due to COVID-19. Higher forced vital capacity (FVC) values tested before COVID-19 were shown to be protective against severe infection (95% CI 0.934-0.98) as well as good control of MG measured by the quantified myasthenia gravis score (95% CI 1.047-1.232). Long-term chronic corticosteroid treatment worsened the course of COVID-19 in MG patients (95% CI 1.784-111.43) and this impact was positively associated with dosage (p = 0.005). Treatment using azathioprine (95% CI 0.448-2.935), mycophenolate mofetil (95% CI 0.91-12.515) and ciclosporin (95% CI 0.029-2.212) did not influence the course of COVID-19. MG patients treated with rituximab had a high risk of death caused by COVID-19 (95% CI 3.216-383.971). Exacerbation of MG during infection was relatively rare (15%) and was not caused by remdesivir, convalescent plasma or favipiravir (95% CI 0.885-10.87). Conclusions As the most important predictors of severe COVID-19 in MG patients we identified unsatisfied condition of MG with lower FVC, previous long-term corticosteroid treatment especially in higher doses, older age, the presence of cancer, and recent rituximab treatment. ER -
JAKUBIKOVA, Michala, Michaela TYBLOVA, Adam TESAR, Magda HORÁKOVÁ, Daniela VLAŽNÁ, Rysankova RYSANKOVA, Iveta NOVAKOVA, Doleckova DOLECKOVA, Dusek DUSEK, Jiri PITHA, Stanislav VOHÁŇKA and Josef BEDNAŘÍK. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival (Letter). \textit{European Journal of Neurology}. Oxford: Rapid Science Ltd., 2022, vol.~29, No~1, p.~''E7''-''E8'', 2 pp. ISSN~1351-5101. Available from: https://dx.doi.org/10.1111/ene.15158.
|